19 NOV 2026

Drones in trials for anti-doping sample delivery

Published Nov 17, 2026
Drones in trials for anti-doping sample delivery

Delivery drones could soon be transporting drug test samples for sports people, after a new study revealed that short-distance quadcopter delivery UAVs can preserve the integrity of anti-doping samples while significantly reducing transport times compared with road transport.

Titled Impact of Drone Versus Car Transport on Anti-Doping Sample Integrity Over Short Distances: A Proof-Of-Concept Study, the research is based on test flights conducted in Doha, Qatar, and forms the first scientific phase of the International Testing Agency’s (ITA) wider “Integrity in Flight” project.

The study reports the results of the proof-of-concept trial conducted in collaboration with the Anti-Doping Laboratory Qatar and Swiss drone maker RigiTech, which manufacturers drones for the delivery of small cargo, including specially reserved medical samples. Blood, urine and Dried Blood Spot (DBS) samples were transported by quadcopter drone and by car over distances of 5 km and 20 km, with a third set of samples remaining unmoved for control purposes.

“In this proof-of-concept study, drone transport of blood, urine and DBS samples was feasible under the conditions tested and produced sample-integrity outcomes comparable to car transport across all four marker categories examined (haematology, urinary steroid profile, routine clinical chemistry and DBS metabolome),” the study reads in part.

Individual steroid concentrations, including testosterone, epitestosterone, androsterone and etiocholanolone, did not differ significantly between car and drone transport at either distance.

“Importantly, the primary steroidal passport marker, the T/E ratio, also remained unchanged across transport modes. Under the WADA steroidal module, interpretation is based on longitudinal steroid ratios, and these findings are consistent with the analytical variation described in WADA Technical Document TD2021EAAS.

“For routine clinical chemistry, no marker differed significantly between car and drone at either distance under the pre-specified threshold, and the smallest observed difference (ALP at 5 km, Δ ≈ 1.0 U/L) fell well within the within-subject biological variability and below the analytical performance specification for ALP.

“This pattern argues against systematic, mode-specific effects. Previous studies have shown that whole-blood tubes exposed to transport-related motion can exhibit small shifts in selected analytes such as LDH and glucose, and although all samples were processed according to standard timelines, the car-transported 20-km samples experienced a longer transit time than the drone (34 min vs. 12 min).

“Even so, no drone-specific deviations in these markers were observed, suggesting that drone transport does not introduce unique stresses beyond those of any transport. Any time- and motion-related effects could be managed by keeping samples cool, minimising transit time and prompt processing.”

The study found no significant differences between car and drone transport for the key haematological, steroidal and routine clinical chemistry biomarkers examined. Across the 664 metabolites detected in DBS samples, 92.3 percent were classified as equivalent between drone and car transport at 5km and 88.0 percent at 20km. No metabolite showed opposing directional changes between the two transport modes.

“The publication of these results is an important milestone for the ITA’s Integrity in Flight project because it provides peer-reviewed scientific evidence that under our experimental conditions, drone transport can be operated while preserving the analytical integrity of anti-doping samples,” said Benjamin Cohen, ITA Director General.

“This gives us a stronger scientific basis to continue exploring where drone technology could provide a practical additional solution for anti-doping, particularly when speed, distance or geography create transport challenges.”

The researchers conclude that, under the conditions tested, drone transport was a feasible alternative to ground transport and had the potential to provide faster delivery while maintaining analytical integrity.

They also note that further validation over longer distances and across a wider range of operational conditions is needed before broader implementation.

ITA experts Dr Mark Stuart OBE, Head of the ITA Academy and a sports pharmacist with extensive experience in anti-doping and medical operations at major sporting events, and Dr Neil Robinson, ITA Head of Science & Medical and an expert in anti-doping sciences, are among the study’s authors. Both contributed to the study design and scientific discussions underpinning the research.

The Qatar trial, conducted n June this year, with the results being made public in September, represents the first phase of the ITA’s broader Integrity in Flight project, a research initiative investigating whether drones can safely, securely, and reliably transport anti-doping samples to accredited laboratories without degrading sample quality.

Rather than replacing traditional ground couriers, the program aims to validate drones as a practical backup for congested cities, major sporting events, and remote or mountainous regions

Building on those findings, the ITA has since extended its research significantly, most recently through a 1,000 km ultra-long-distance test flight in Nenana, Alaska, in August 2026. That study is examining whether blood parameters relevant to the Athlete Biological Passport remain stable during much longer drone journeys and under a very different operational environment.

“Together, the Qatar and Alaska studies reflect a progressive research approach: first establishing feasibility over short distances, then testing the concept over far greater distances and in more demanding conditions.”

Comments

Join the discussion

0 Comments

What people are saying

No comments yet. Be the first to comment!

Leave a comment

Maximum 2000 characters 0 / 2000
Your comment will be reviewed before being published